Clinical Trials Logo

FAP clinical trials

View clinical trials related to FAP.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06387381 Recruiting - Clinical trials for Positron-Emission Tomography

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

Start date: May 20, 2024
Phase: Early Phase 1
Study type: Interventional

As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.

NCT ID: NCT06189820 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

FAPIPET
Start date: March 9, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

NCT ID: NCT05873777 Recruiting - Clinical trials for Positron-Emission Tomography

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Start date: April 9, 2023
Phase: N/A
Study type: Interventional

As a new dual receptor (SSTR2 and FAP) targeting PET radiotracer, 68Ga-FAPI-LM3 is promising as an excellent imaging agent applicable to SSTR2 positive diseases. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-LM3 in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga-FAPI-LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of lesions in SSTR2 positive diseases, and compared with 18F-FDG PET/CT.

NCT ID: NCT05692596 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Start date: October 6, 2022
Phase:
Study type: Observational

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

NCT ID: NCT05262855 Recruiting - Clinical trials for PDAC - Pancreatic Ductal Adenocarcinoma

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

FAPI-46 PDAC
Start date: May 2, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.

NCT ID: NCT05262647 Recruiting - Liver Fibrosis Clinical Trials

18F-FAPI PET in the Diagnosis of Liver Fibrosis

Start date: December 12, 2021
Phase:
Study type: Observational [Patient Registry]

It is an open label observation clinical trial, all participants are chronic liver disease. The investigators deem to make a novel evaluate criteria to hepatic fibrosis. The point of the clinical trial is to evaluate the novel biomaker 18F-FAPI-04 by PET-CT scan in the evaluation of the hepatic fibrosis.